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Abstract 
Huntington’s disease (HD) is an autosomal neurodegenerative disorder affecting approximately 
5-10 persons per 100,000 worldwide.  The pathophysiology of HD is not fully understood but the 
age of onset is known to be highly dependent on the number of CAG triplet repeats in the 
huntingtin gene.  Using 1H NMR spectroscopy this study biochemically profiled 39 brain 
metabolites in post-mortem striatum (n=14) and frontal lobe (n=14) from HD sufferers and 
controls (n=28). Striatum metabolites were more perturbed with 15 significantly affected in HD 
cases, compared with only 4 in frontal lobe (P<0.05; q<0.3). The metabolite which changed most 
overall was urea which decreased 3.25-fold in striatum (P<0.01).  Four metabolites were 
consistently affected in both brain regions. These included the neurotransmitter precursors 
tyrosine and L-phenylalanine which were significantly depleted by 1.55-1.58-fold and 1.48-1.54-
fold in striatum and frontal lobe, respectively (P=0.02-0.03). They also included L-leucine which 
was reduced 1.54-1.69-fold (P=0.04-0.09) and myo-inositol which was increased 1.26-1.37-fold 
(P<0.01). Logistic regression analyses performed with MetaboAnalyst demonstrated that data 
obtained from striatum produced models which were profoundly more sensitive and specific than 
those produced from frontal lobe.  The brain metabolite changes uncovered in this first 1H NMR 
investigation of human HD offer new insights into the disease pathophysiology. Further 
investigations of striatal metabolite disturbances are clearly warranted.  
Keywords: Huntington’s disease; metabolomics; 1H NMR; brain; metabolites.  
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Introduction  
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by the 
extension of a CAG repeat at exon 1 of chromosome 4 (4p63) and is clinically characterized by 
chorea and dystonia, cognitive decline and behavioural changes 1-6.  It affects 30,000 US citizens 
(1 in every 10,000) and it is estimated that an additional 150,000-200,000 are at greater risk 
because they have at least one parent with HD 7.  The appearance of symptoms is inversely 
correlated to the number of CAG repeats, which is also an influential factor in determining the 
age of HD onset (it is responsible for ~50-70% of the variance) 8. The unaffected range is 
(CAG)6-35 repeats, alleles of (CAG)>40 are considered fully penetrant and these individuals carry 
a 100 % lifetime risk of developing HD and CAG repeat size with alleles of (CAG)>60 causes 
juvenile onset.  Although HD can present itself at any age, the age of onset is typically 40-45 
years with death typically occurring 15-20 years after the initial manifestation 3,9-11.  Currently 
there is no neuroprotective therapy 3 or ultimate “cure” for this debilitating neurodegenerative 
disease 5,8.  
There are major knowledge gaps regarding the underlying biomolecular mechanisms of HD 
2,11. However, there is some evidence that mechanisms contributing to HD pathogenesis include: 
polyglutamine aggregation and misfolding 12, oxidative stress and mitochondrial dysfunction 9, 
misregulation of energy expenditure 10, transcriptional deregulation 13,14, excitotoxicity 15,16 and 
dopamine toxicity 17,18.  Despite research advances in the last two decades there has been no 
meaningful progress in medical treatments for HD.  Few drugs are available for HD treatment 
and these offer only symptomatic relief (of chorea only) 2.  The most promising research to date 
has been with co-enzyme Q10 (currently in Phase 3 clinical trial (n=608 participants); 2Care, 
The Huntington Study Group) which acts in part to enhance mitochondrial anti-oxidative and 
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free radical scavenging mechanisms 8. The aim would be to target new treatments to pre-
manifest patients as the discovery that changes due to HD happen many years prior to 
diagnosable onset.  Significant technological advances now make it possible to measure, screen 
and identify thousands of potential biomarkers in biosamples.  There is an unprecedented 
opportunity to identify reliable “state” biomarkers of pre-manifest HD progression that can be 
used as outcome measures in preventative clinical trials. 
 Most biomarker research in HD has concentrated on identifying clinical and 
neuroimaging biomarkers of disease.  Clinical biomarkers are standardised clinical tests and 
rating scales that measure the progression of various characteristics of the HD phenotype, such 
as cognition and motor deterioration 3. Data from the full PREDICT-HD study reported that a 
standardised cognitive tasks (n=51) demonstrate psychomotor processing, emotion recognition 
and working memory to be very sensitive when differentiating individuals according to time to 
predicted HD onset 3,19. However clinical biomarkers are limited when differentiating between 
symptomatic improvement and progression of the disease 20.  Additionally they seldom provide 
any information pertaining to the fundamental disease mechanisms or disease pathogenesis, 
emphasizing the need for additional non-clinical biomarkers 3.   
Very few studies have investigated the potential of metabolomics methodologies to discover 
novel biochemical biomarkers for HD. A range of studies have demonstrated the utility of 
metabolomic profiling techniques in accurately distinguishing neurodegenerative diseases from 
healthy controls 9,10,21-30.  Indeed, it has been successful in identifying plasma biomarker panels 
for the clinical diagnosis of Alzheimer’s disease (AD) in individuals with amnestic mild 
cognitive impairment 31. However there is a significant paucity of reliable “state” biomarkers 
which accurately discriminates pre-manifest HD from manifest HD. The majority of HD 
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metabolomics experiments have been conducted with rodent models which mimic some of the 
pathology of human HD.  For instance Tsang et al., (2005) used proton nuclear magnetic 
resonance (1H NMR) and magic angle spinning NMR (MAS-NMR) to discriminate between 
R6/2 HD transgenic mice and wild-type controls.  In this study they analysed skeletal tissue, 
post-mortem (PM) brain, serum and urine from mice aged 4, 8 and 12 weeks.  They highlighted 
metabolite differences and potential pathways that may be affected 11. Underwood et al., (2006) 
applied GC-Tof-MS metabolite profiling techniques to serum samples from human HD patients 
(prodromal) and a transgenic mouse model in their search for biomarkers.  They identified 1275 
metabolite peaks but none of their predictive models reached statistical significance.  However, 
they did find that fatty acid β-oxidation and nucleic acid breakdown were commonly affected in 
human and murine models 10.  Verwaest et al., (2011) applied 1H NMR metabolomics to study 
the difference between transgenic mice and WT-control litter mates using CSF and serum.  They 
produced multivariate models which distinguished between transgenic mice and WT controls 
with 84.9% and 72.73% predictive power for serum and CSF, respectively. In addition they 
produced support vector machine models; one of which was capable of differentiating between 
transgenic mice and WT controls with a receiver operating characteristics (ROC) value of 0.71 
for serum. Unfortunately no significant differences where observed within the SVM model 
created from CSF data, but the study did suggest that mitochondrial energy dysfunction occurs in 
HD 9.  Chang et al., (2011) applied GC-Tof-MS metabolomic profiling to the plasma and brain 
tissue of the 3-NP early stage HD rat model (proposed as a model of pre-manifest HD).  They 
produced predictive models which weakly differentiating transgenic mice from WT-controls 
with 52.4% and 30.2 % accuracy for brain and plasma, respectively 29.  Having reviewed the 
current literature (described above) we can conclude that progress in this research field has been 
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hampered by a lack of studies involving human HD specimens.  Therefore, we undertook 1H 
NMR biochemical profiling of the polar metabolome of post-mortem human brain from two 
different regions (frontal lobe and striatum) from HD patients and aged-matched control 
subjects.  The aim was to identify novel CNS biomarkers of HD, and also to discover previously 
unknown fronto-striatal perturbations associated with the onset of HD. 
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Materials and Methods 
Samples 
Brain tissue specimens (frontal lobe and striatum) were obtained from post-mortem HD cases 
(n=14) and also from control subjects (n=14) with no apparent Huntington’s pathology.  All HD 
cases showed a moderately to severely atrophied corpus striatum consistent with grades 2 or 3.  
Exact CAG repeat numbers were not available; the clinical diagnosis of HD was confirmed by 
genetic testing in all cases, except cases BBN_3211 and BBN_6070. Diagnosis of HD in these 
instances was made by the presence of ubiquitinated/p62 positive intra-nuclear inclusions within 
cortical and striatal neurons. All other HD cases also demonstrated such inclusions. None were 
observed in the control cases.  Details such as Vonsattel grading, age, gender, race and post-
mortem delay can be found in Supplementary Table 1. Tissues were obtained from the 
University of Manchester Brain and Tissue Bank.   
Sample Preparation 
Frozen tissue samples (∼5 g) were lyophilized (Christ Freeze Dryer, IMA Life, USA) and milled 
to a fine powder (Freezer/Mill 6870, Spex Sample Prep, USA) and 50 mg (±0.5 mg) was added 
to 500 µL of 50% methanol/water in a 2 mL sterile Eppendorf tube. The samples were mixed for 
10 min, sonicated for 20 min and the protein removed by centrifugation at 13,000 g at 4 °C for 
20 min 21,22.  Supernatants were collected, dried under vacuum using a Savant DNA Speedvac 
(Thermo Scientific, USA) and reconstituted in 285 µl of 50 mM sodium phosphate buffer (pH 
7.0), 30 µl of  Sodium 2,2-dimethyl-2-silapentane-5-sulfonate (DSS) and 35 µl of D2O 32.  200 µl 
of sample was transferred to a 3 mm Bruker NMR tube for NMR analysis.  All samples were 
housed at 4°C in a thermostatically controlled SampleJet autosampler (Bruker-Biospin, USA).  
Graham et al 
03/04/2016 
8 
 
Prior to analysis by NMR, samples were heated to room temperature over a 3 min before being 
transferred to the magnet. 
NMR Analysis 
All 1H-NMR experiments were recorded at 300.0 (±0.05) K on a Bruker Avance III HD 600 
MHz spectrometer (Bruker-Biospin, USA) operating at 600.13 MHz equipped with a 5 mm TCI 
cryoprobe. Using a randomized running order 1D 1H-NMR spectra were acquired using a pulse 
sequence developed by Ravanbakhsh et al. (2015) 33. Two hundred and fifty six transients were 
acquired. Chemical shifts (d) are reported in parts per million (ppm) of the operating frequency.  
The singlet produced by the DSS methyl groups was used as an internal standard for chemical 
shift referencing (set to 0 ppm, concentration 500 µM) and for quantification, all 1H-NMR 
spectra were processed and analysed using an in-house version of the Bayesil NMR automation 
software 33. Bayesil is a web based system that automatically identifies and quantifies 
metabolites based on a library of pure compounds. 
Statistical Analysis 
For the comparisons of each NMR metabolite, a Student’s t-test was performed. In the case of 
non-normal distributions, p-values were calculated based on the Mann-Whitney U test. P-values 
< 0.05 were considered statistically significant. Bonferroni corrected p-values (p=0.05/number of 
metabolites) were used to correct for multiple comparisons. Multivariate statistical analysis was 
used to determine if a predictive model could be produced based on the concentrations of the 
identified metabolites to differentiate between the two brain regions (frontal lobe and striatum) 
and the controls. Data were log-transformed and Pareto-scaled prior to using Principal 
Component Analysis (PCA) and Partial Least Squares Discriminant Analysis (PLS-DA).  The 
variable importance in projection (VIP) plot that ranks the metabolites in order of their 
Graham et al 
03/04/2016 
9 
 
importance to a predictive model was generated. The greater the score on the x-axis is the greater 
the significance of that metabolite to the generated PLS-DA model. The PLS-DA models were 
subsequently subjected to permutation testing (2,000 iterations) to establish whether the observed 
discrimination between the groups was statistically significant (p-value < 0.05).  
Logistic regression analysis was performed with the generalized log-transformed data. The 
stepwise variable selection was also utilized for optimizing all the model components. 
Furthermore, a k-fold cross-validation (CV) technique was used to ensure that the logistic 
regression models were robust 41. In k-fold CV, the entire sample data is randomly divided into k 
equal sized subsets. Of the k subsets, only one subset is used as the validation data for testing the 
model, and the remaining (k-1) subsets are used as training set to generate the model. This results 
in predictive biomarker predictive models that are both robust and optimal.  
To determine the performance of each generated model, the area under the receiver operating 
characteristics curve (AUROC or AUC) was calculated with sensitivity and specificity using 
previously described techniques 34.  A receiver operator characteristic (ROC) curve is plotted 
with sensitivity values on the Y-axis and the corresponding FPR (1-specificity) on the X-axis. 
The area under the ROC curve (AUC) indicates the accuracy of a test for correctly distinguishing 
cases from controls. An AUC=1 indicates perfect discrimination. The 95 % CI for the AUC 
curves were also calculated.  All these analyses were performed using the MetaboAnalyst 
software 35-38.  
Pathway Analysis 
Metabolites that were found to be significantly different (p-value<0.05) between HD and 
controls were analyzed using the pathway topology search tool in Metaboanalyst (v 3.0) 35-37. 
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The pathway library chosen was for Homo sapiens (human) and all compounds in selected 
pathways were used when referencing the specific metabolome.  Fisher’s exact test was applied 
to perform over-representation analysis and “relative betweeness centrality” was chosen for the 
pathway topology testing.  Pathways that had both a Holm adjusted p-value <0.05 and FDR p-
value <0.05 were considered to be altered due to HD.    
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Results 
Figure 1 displays a labelled 1H NMR spectrum of the extract taken from the frontal lobe of PM 
human brain of a HD sufferer.  In total 39 metabolites were accurately identified and quantified 
using 1H NMR.  Figure 2a and 2c display the PLS-DA scores plots for both frontal lobe and 
striatum from controls vs. HD sufferers, respectively.  The scores plots show good separation 
between the two sample sets.  Extracts from striatum produced better models with greater 
separation compared with frontal lobe extracts.  Figures 2b and 2d display the variable 
importance in projection (VIP) plots for both the frontal lobe and striatum discriminant models, 
respectively.  These two VIP plots rank the metabolites in order of their importance to the 
predictive models.  The greater the height on the x-axis the greater the significance of that 
metabolite to that particular model. In addition following 2000 rounds of permutation testing the 
probability of each model being statistically significant (p<0.05) were p=0.025 and p=0.0004 for 
the frontal lobe and striatum, respectively.  With these p-values, extracts from the striatum were 
found to produce better models with increased separation in comparison with frontal lobe 
extracts.  
 Table 1 lists the results of the univariate analysis of all the metabolites recorded and 
quantified in the frontal lobe of controls and HD sufferers.   Of the 39 metabolites only 4 reached 
statistical significance (p<0.05; q<0.3).  These include tyrosine, l-phenylalanine, myo-inositol 
and l-leucine. Using the concentration data a pathway analysis was completed and it found that a 
total of 5 pathways were disrupted as a result of HD.  However when stringent thresholds (Holm 
Adjusted p-value<0.05; q<0.05) were placed on these results only 3 pathways were found to be 
affected.  These included inositol phosphate metabolism, galactose metabolism and ascorbate 
and aldarate metabolism (Supplementary Table 2). 
Graham et al 
03/04/2016 
12 
 
 Table 2 lists the results of the univariate analysis of all the metabolites recorded and 
quantified in striatum from control and HD sufferers.  Of the 39 metabolites 15 were recorded as 
being significantly different (p<0.05; q<0.3) between HD and controls.  As for the frontal lobe a 
pathway analysis was performed to determine which biochemical pathways are affected as a 
direct result of HD in the striatum.  A total of 7 pathways were detected as being disrupted as a 
result of HD; however this number was reduced to 4 when we applied the same thresholds for 
significance as previously (P<0.05; q<0.05).  The remaining pathways include: Inositol 
phosphate metabolism, galactose metabolism, glyoxylate and dicarboxylate metabolism and 
ascorbate and aldarate metabolism (Supplementary Table 3).  
PLS-DA analysis was conducted to determine differences between the two brain regions.  
Figure 3a displays the results of the PLS-DA analysis between control subjects taken from 
frontal lobe and striatum.  As is evident complete separation was achieved (p=0.003 following 
permutation testing; 2,000 repeats).  Figure 3c shows the PLS-DA scores plot from HD sufferers 
taken from both the frontal lobe and striatum (p<0.001 following permutation testing; 2,000 
repeats).  Here also there was complete separation of the two brain regions.  Figures 3b and 3d 
display the VIP plots for the control and HD regions, respectively.  As may have been expected 
different metabolites were responsible for the variation between regions collected from controls 
and the regions collected from HD patients.  Supplementary Table 4 displays the results of the 
univariate analysis for frontal lobe extracts vs. striatum extracts from controls. Of the 39 
metabolites a total of 6 metabolites were deemed to be statistically different (p<0.05; q<0.3) 
between the two regions. Supplementary Table 5 displays the univariate analysis for frontal lobe 
extracts vs. striatum extracts from HD cases. Of the 39 metabolites identified and quantified only 
7 were found to be at statistically significantly different concentrations between the two regions.  
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Figure 4a shows the results of ROC analysis undertaken using the concentrations of tyrosine, L-
leucine and L-phenylalanine for control vs. HD data acquired from the frontal lobe extracts. 
During the process of selecting the best performing model it was deemed necessary to exclude 
myo-inositol from the PLS-DA model.  An AUC of 0.752 (0.539-0.92) was achieved and 
following permutation testing (1000 repeats) a p-value of 0.108 was achieved demonstrating that 
the model does not reach significance when analysed using the PLS-DA algorithm.  Figure 4b, 
displays the results of the logistic regression model ROC analysis following 10 fold cross 
validations.  After performing the stepwise variable selection with the significantly different 
metabolites (p < 0.05), a logistic regression algorithm was created using the concentrations of 
tyrosine alone in the frontal extracts.  The formula for the logistic regression algorithm is as 
follows: 
The formal equation of the logistic regression model is written as logit(π) = β0 + β0X1 + β2X2 +… 
+ βkXk, where π is the probability of the proportion of HD case in a group, and Xi is the 
metabolite concentrations as k covariates. logit(π) =   – 0.006 – 1.439 Tyrosine, where 0.43 is the 
threshold.  The performance values for both the ROC analysis and the logistic regression 
algorithm are available as Tables 3a and 3b, respectively. 
Figure 4c displays the results of the ROC analysis calculated using the concentrations of 
urea, valine, tyrosine and 4-aminobutyrate for control vs HD data acquired using striatum 
extracts.  An AUC of 0.917 (CI: 0.75-1) was calculated and following permutation testing (1000 
repeats) for the ROC analysis, the PLS-DA model reached significance (p=0.015). Figure 4d 
displays the ROC results of the logistic regression model created using the concentrations of 
tyrosine and urea with a 10-fold cross validation applied. The logistic regression algorithm for 
these two metabolite concentrations in striatum is:   
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The formal equation of logistic regression model is written as  
 logit(π) = – 0.594 – 3.068 Tyrosine – 2.421 Urea, where a threshold is 0.43 is applied.  The 
performance values for both the ROC analysis and logistic regression algorithm are available in 
table 4a and 4b, respectively. 
Pathway analysis showed which biochemical pathways differed between the two regions under 
for Control cases and for HD patients. For control subjects only Butanoate metabolism was 
found to be significantly different (Holm adjusted P=0.006; fdr=0.006) between the two regions.  
However, 7 biochemical pathways were found to be affected across the two regions in HD 
brains, and of these only glycoxylate and dicarboxylate metabolism reached statistical 
significance (Holm adjusted p=0.0002; q=0.0002).  The results are summarised as 
Supplementary Table 6. 
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Discussion 
This is the first 1H NMR based metabolomic investigation of human HD brain.  We analysed 
specimens collected from two brain regions: the frontal lobe and the striatum. The decision to 
focus on these regions was based on the fact that fronto-striatal circuitry dysfunction is a 
recognized clinical feature of HD 39.  Using the 1H NMR data acquired we confidently identified 
and quantified 39 metabolites in both brain regions.  Metabolite concentration data led to the 
development of two multivariate discriminant models which accurately differentiated between 
the control and HD specimens for both the frontal lobe and striatum (p=0.003 and p<0.001 
following permutation testing, respectively; 2,000 repeats). 
 Importantly, we observed different metabolites to be significantly affected in the two 
brain regions.  This heterogeneity demonstrates that the biochemistry in these two anatomical 
regions is perturbed to different extents after the onset of HD.  Analysis of frontal lobe showed 
that the concentrations of four metabolites were significantly perturbed in HD compared with 
control extracts.  In this instance we have based significance on p<0.05 and q<0.3 due to the 
small sample number, and also the small number of metabolites identified and quantified in this 
study.  The metabolites which significantly differed between controls and HD sufferers in the 
frontal lobe included:  tyrosine, L-phenylalanine, myo-inositol and L-leucine (Table 1). 
 Analysis of striatum revealed that 15 metabolites were significantly perturbed in HD 
compared with control extracts (Table 2).  These include: 4-aminobutyrate, glycine, formate, L-
glutamic acid, tyrosine, L-phenylalanine, aspartate, inosine, myo-inositol, taurine, urea, uracil, L-
leucine, valine and niacinamide (Table 2).  Only four metabolites tyrosine, L-phenylalanine, 
myo-inositol and L-leucine differed across both brain regions.  There was however a degree of 
consistency in the responses we observed. Tyrosine, L-phenylalanine and L-leucine were always 
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decreased in HD brain and myo-inositol was consistently increased.  Tyrosine is an essential 
amino acid which readily crosses the blood-brain barrier (BBB).  Tyrosine is a precursor for the 
biosynthesis of the neurotransmitters of the sympathetic nervous system (i.e. dopamine, 
norepinephrine and epinephrine).  L-phenylalanine is a precursor of tyrosine, therefore making 
L-phenylalanine also precursor of these catecholamine neurotransmitters. Hyperactivity of the 
sympathetic nervous system has been reported in HD sufferers40, and it could be speculated that 
increased neurotransmitter biosynthesis leads to depletion of tyrosine and L-phenylalanine 
precursors in both the frontal lobe and striatum.   
L-leucine is one of three essential branched chain amino acids (BCAA) which regulates 
protein synthesis by activating mTor (mammalian target of rapamycin)41, increases reutilization 
of amino acids and reduces protein breakdown (www.HMDB.ca).  The results here corroborate 
earlier findings that L-leucine is lower in HD patients42,43.  The strong correlation between 
essential amino acids and IGF-1 has been extensively described 44,45,46.  Interestingly Mochel et 
al., report a correlation between low BCAA levels  and IGF-143 with  IGF-1 known to activate 
the serine-threonine Akt pathway to which huntingtin is a substrate47.  The potential disease 
relevance is that decreased activation of this particular biochemical pathway has been linked to 
the neuronal toxicity resulting from the reduced phosphorylation of the mutated huntingtin 
protein43.  
Myo-inositol is a cyclic polyalcohol playing an important second messenger role (inositol 
phosphates) in the cell (www.HMDB.ca). Myo-inositol is considered to be a strong a 
marker/indicator of gliosis48 with the prototypical biochemical change being the increase in glia 
fibrillary acid protein.  This change is common to all forms of brain injury characterized as an 
increase in astrocyte cell body and its processes 49.  Here, myo-inositol is significantly elevated in 
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HD brain50 which can be directly correlated to an increase in gliosis as the disease progresses 
across the frontal-striatal circuits.     
Using the acquired data we examined brain region-specific differences in the metabolome 
of the frontal lobe and the striatum. There was complete separation of frontal lobe and striatum 
(figures 3a and 3c) both when the controls were selected or the HD cases. However, the top 
ranking measured metabolites (in terms of VIP scores) differed substantially for the control and 
HD scores plots (Figures 3b and 3d, respectively).  Univariate statistical examination of control 
frontal lobe and striatum found six metabolites to significantly (p<0.05; q<0.3) differ between 
the two brain regions (Supplementary Table 4).  These included: 4-aminobutyrate, ethanolamine, 
inosine, homocitrulline, N-acetylaspartic acid (NAA) and niacinamide.  Similarly, for HD cases 
a total of seven metabolites significantly differed (p<0.05; q<0.3) between the two brain regions 
(Supplementary Table 4).  These included: formate, L-glutamic acid, ethanolamine, myo-inositol, 
succinate, homocitrulline and NAA.  We then eliminated those metabolites which significantly 
differed between controls and HD.  This enabled us to focus entirely on those fronto-stratial 
metabolite changes which were impacted by HD pathology.  These metabolites were formate, 
myo-inositol and succinate which were all increased in striatum, and also L-glutamic acid which 
was increased in the frontal lobe.  Formate or formic acid is an intermediary metabolite under 
normal metabolic conditions.  It plays a role in metabolic acidosis and inhibiting cytochrome 
oxidase activity (terminal electron in the electron transport chain) leading to cell death by 
depleting ATP reserves and producing reactive oxygen species.  Succinate (the anion of succinic 
acid) is a component of the citric acid cycle which is capable of donating electrons to the 
electron transfer chain (www.HMDB.ca).  Higher concentrations of both succinate and formate 
in the striatum could suggest that both the citric acid cycle and electron transfer chain are 
Graham et al 
03/04/2016 
18 
 
significantly reduced in the frontal lobe.  Higher concentrations of myo-inositol could indicate 
that gliosis is more prevalent in the striatum than the frontal lobe. L-glutamic acid (glutamate) is 
the most abundant fast excitatory neurotransmitter in the mammalian nervous system.  Lower 
glutamate levels in the striatum would seem to fit with the higher levels of myo-inositol and 
increased gliosis.  Following the synaptic release of neurotransmitters, glia cells restrict diffusion 
and inactivate and recycle a variety of neurotransmitters to include: glutamate, GABA and 
catecholamines 51,52. Decreased concentration of glutamate in the striatum suggests glial damage 
has occurred. Taken together with the increased concentrations of myo-inositol this suggests that 
there is more gliosis in the striatum than the frontal lobe.      
One of the main findings of this study is that HD pathology has a much greater effect on 
biochemical perturbations in the striatum than it does in the frontal lobe.  In addition to the 
multivariate analysis we undertook logistic regression analyses and this demonstrated that the 
data obtained from the striatum extracts produced logistic regression models with increased 
sensitivity and specificity following a 10-fold cross validation (Table 3 and 4; frontal lobe and 
striatum, respectively).  In addition, frontal lobe data (unlike the striatum) produced a PLS-DA 
model which failed to reach any statistical significance (p=0.108) following 1,000 permutation 
tests.  The PLS-DA model created with striatum data did reach statistical significance following 
cross validation (1000 permutation tests; p=0.015) which enabled us to be confident that the 
algorithm developed using the striatum data is accurate for the identification of controls from HD 
sufferers based on the concentrations of tyrosine and urea evident from the equation. 
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Conclusions 
This first 1H NMR metabolomics investigation examined how HD affects two regions of the 
human brain and identified a number of biochemical changes. The metabolite data produces 
statistical models that accurately discriminate between the striatum of control subjects and HD 
patients. Metabolites identified here could be considered potential biomarkers for detecting and 
monitoring HD and perhaps in vivo magnetic resonance spectroscopy methodologies could be 
employed here.  The major metabolites which were significantly affected (p<0.05) in the frontal 
lobe of HD specimens were L-leucine, myo-inositol, L-phenylalanine and tyrosine.  Those 
metabolite concentrations significantly different (p<0.05) in the striatum of HD specimens were: 
4-aminobutyrate, aspartate, formate, L-glutamic acid, glycine, inosine, L-leucine, niacinamide, 
myo-inositol, L-phenylalanine, taurine, tyrosine, uracil, urea and valine.  This study 
demonstrates the suitability and potential power of applying NMR-based metabolomics protocols 
for the study of HD. Indeed more metabolomic methodologies could be focused on HD. For 
instance, there are rodent models of HD available which could allow a longitudinal examination 
of the changes occurring in blood and brain metabolome. This approach has recently been 
demonstrated for Alzheimer’s disease-like pathology 53. Also, the use of larger sample sizes and 
different sample types could enable researchers to identify the earliest signs of disease (pre-
manifest HD). In the long-term the discovery of metabolite biomarkers could improve patient 
stratification and in turn improve clinical trial outcomes which could aid in the development of 
disease-modifying therapies for HD.  
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Figure Legends 
Figure 1. NMR spectroscopy of Huntington Disease (HD) brain extract (Frontal lobe). 
Typical 1D 1H NMR spectrum of a polar extract taken from HD striatum with identified 
metabolites labelled in the aliphatic (a) and aromatic regions of the spectrum (b). 1, 1-
Methylhistidine; 2, Adenine; 3, Acetic Acid; 4, Ascorbic Acid; 5, Creatine; 6, 
Glycerophosphocholine; 7, Choline; 8, 4-Aminobutyrate; 9, Glycine; 10, Formate; 11, L-
Glutamic Acid; 12, Ethanolamine; 13, Hypozxanthine; 14, Tyrosine; 15, L-Phenylalanine; 16, L-
Alanine; 17, L-Threonine; 18, Isoleucine; 19, L-Lactic Acid; 20, Aspartate; 21, Anserine; 22, 
Inosine; 23, Myo-inositol; 24, Taurine; 25, Succinate; 26, Urea; 27, Uracil; 28,  3-
Hydroxybutyric acid; 29, Adenosine triphosphate; 30, L-Glutamine; 31, Homocitrulline; 32, L-
Leucine; 33, N-Acetylaspartic Acid; 34, Valine; 35, Niacinamide; 36, Phosphorylcholine; 37, 
Isobutyric acid; 38, Propylene glycol; 39, Glutathione-Oxidised. 
Figure 2.  Multivariate comparisons of control and HD. (a) the PLS-DA (showing the 
separation between groups) scores plot of control (n=14; blue dots) vs. HD (n=14; red crosses) 
data from the frontal lobe; (b) the VIP plot (showing the metabolites most important for 
classifying groups) for the frontal lobe data; (c)  the PLS-DA scores plot of control (n=14; blue 
dots) vs. HD (n=14; red crosses) data from the striatum region of  the brain; (d) the VIP plot for 
the striatum region data. 
Figure 3.  Multivariate comparisons of striatum and frontal lobe. (a) the PLS-DA scores plot 
of frontal lobe (n=14; blue dots) vs. the striatum region (n=14; red crosses) from the control 
cases; (b) the VIP plot for the control data; (c) the PLS-DA scores plot of frontal lobe (n=14; 
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blue circles) vs. striatum region (n=14; red dots) from the HD cases; (d) the VIP plot for the HD 
cases. 
Figure 4. Receiver operating characteristics (ROC) curve analysis of metabolite data. (a) 
the ROC analysis illustrates the performance of metabolites as biomarkers discriminating control 
vs. HD in the frontal lobe.  AUC: 0.752 (CI: 0.539-0.92); (b) logistic regression ROC analysis of 
control vs. HD of frontal lobe data following 10-fold cross validations. AUC: 0.745 (CI: 0.558-
0.931); (c) the ROC analysis for control vs. HD data acquired from striatum.  AUC: 0.917 (CI: 
0.75-1.00); (b) logistic regression ROC analysis of control vs. HD from striatum following 10-
fold cross validations. AUC: 0.838 (CI: 0.673-1.00). 
 
  
